Ranibizumab in the Treatment of Patients With Visual Impairment Due to Diabetic Macular Edema

Clinical Ophthalmology - New Zealand
doi 10.2147/opth.s17423
Full Text
Abstract

Available in full text

Categories
Ophthalmology
Date
Authors
Publisher

Informa UK Limited

Related search

Cost-Effectiveness of Ranibizumab Versus Aflibercept in the Treatment of Visual Impairment Due to Diabetic Macular Edema: A UK Healthcare Perspective

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2015English

The Macular Function and Structure in Patients With Diabetic Macular Edema Before and After Ranibizumab Treatment

Documenta Ophthalmologica
OphthalmologySensory SystemsPhysiology
2016English

Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema

JAMA Ophthalmology
Ophthalmology
2018English

Comparison Study of Efficacyinvolving Intravitreal Ranibizumab Versus Standard Laser Mono Therapy in Patients With Visual Impairment Due to Diabetic Macula Edema

IOSR Journal of Dental and Medical Sciences
2017English

Intravitreal Ranibizumab for Diabetic Macular Edema With Prompt Versus Deferred Laser Treatment

Ophthalmology
Ophthalmology
2012English

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

Ophthalmology
Ophthalmology
2016English

Sub-Macular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema

Case Medical Research
2019English

Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema

JAMA Ophthalmology
Ophthalmology
2016English

Pss34 - Cost-Effectiveness of Intravitreal Aflibercept Versus Ranibizumab in the Treatment of Diabetic Macular Edema in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy